Navigation Links
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
Date:12/9/2008

Studies Presented at American Epilepsy Society Annual Meeting

ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- UCB today announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extended-release tablets comparing tolerability versus levetiracetam immediate release (IR) and reporting on additional dosing schedules. The data were among five studies that were presented at the 62nd annual meeting of the American Epilepsy Society (AES) in Seattle.

Keppra XR was approved by the U.S. Food and Drug Administration in September 2008 for use as adjunctive treatment for people with partial-onset seizures who are 16 years of age and older.

"In this new meta-analysis, patients taking Keppra XR experienced fewer nervous system side effects than those taking the same dose of twice daily levetiracetam," said James Zackheim, Medical Director, CNS, UCB. "Keppra XR is the only once-daily, extended-release formulation of levetiracetam, and there is no generic alternative available."

Summary of Keppra XR Data Presented at 2008 AES Annual Meeting

Safety Profile of Levetiracetam Extended Release Compared to Immediate Release: An Indirect Comparison Using a Meta-Analytic Approach

Researchers conducted a meta-analysis of Phase III data to determine whether Keppra XR is associated with any tolerability advantages versus the same daily dose of levetiracetam IR. According to the meta-analysis, patients taking Keppra XR once-daily had lower rates of some adverse events versus levetiracetam IR twice-daily.

-- In terms of overall tolerability, 52.8% of Keppra XR patients reported any adverse event, compared with 79% of patients taking levetiracetam IR.

-- While adverse events associated with levetiracetam IR were also observed with Keppra XR, patients treated with Keppra XR once
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
2. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
3. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
4. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
5. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
6. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
7. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
10. Opportunities to Highlight Type 1 Diabetes in November
11. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Net Medical Xpress Solutions, ... market, announced today the company has signed a letter ... company based in Huntsville, AL . ... in the staffing and recruitment of telemedicine physicians. Consideration ... the final agreement, which is expected by June 30, ...
(Date:5/23/2013)... , May 23, 2013  Datameer announced today ... enable data discovery on their big data platform. ... tools they need to quickly and easily visualize ... A Fortune 19 company, Cardinal Health is ... It provides pharmaceuticals and medical products to more ...
(Date:5/23/2013)... 23, 2013  Omeros Corporation (NASDAQ: ... Drug Application (IND) to evaluate OMS824 in Huntington,s ... and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase ... the brain linked to a wide range of ... schizophrenia. OMS824 has shown promising results in animal ...
Breaking Medicine Technology:Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3Cardinal Health Selects Datameer for Healthcare Data Discovery 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4
... March 29, 2007 /PRNewswire-FirstCall/ -- ADVENTRX,Pharmaceuticals, ... company focused on commercializing proprietary product,candidates ... infectious diseases,announced today that results from ... with intravenous 5-fluorouracil (5-FU),and capecitabine (Xeloda(R)), ...
... 2007--For depressed people with bipolar,disorder who are taking ... more effective than a placebo (sugar pill),according to ... the New,England Journal of Medicine. The results are ... Bipolar Disorder (STEP-BD), a $26.8 million clinical trial,funded ...
Cached Medicine Technology:ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 2ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 3Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 2Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 3
(Date:5/23/2013)... York (PRWEB) May 23, 2013 ... C.R. Bard, Inc., continue to move forward in a ... District of West Virginia, Bernstein Liebhard LLP reports. ... denied a request by C.R. Bard to seal emails ... trade secrets and other confidential, proprietary information about its ...
(Date:5/23/2013)... Spring and summer have always been motivation ... Jackson , the city between Memphis and Nashville? In the ... wellness centers has transformed the growing area into one of ... any city of vibrant, young professionals you are going to ... Kim White, owner of The Fight Shop, one of the ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Parker Waichman ... rights of victims injured by defective medical devices and ... Matthew J. McCauley has been appointed Co-Lead Counsel in ... IUD Products Liability Litigation (Case 7:13-md-02434-CS). The Order, which ... Liaison Counsel are to submit their proposal for the ...
(Date:5/23/2013)... News) -- The sensation of itching is hardwired into ... a small molecule released in the spinal cord, according ... say this molecule, known as natriuretic polypeptide b (Nppb), ... system. Ultimately, this signal is experienced as an itch. ... similar, the researchers concluded that a similar process probably ...
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- A shortage of ... health departments across the United States to contain the ... report. The drug, isoniazid (INH), was first used ... to be the core of any first-line treatment for ... to nine months, according to the U.S. Centers for ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 2Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 3Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 4Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2
... Pa., Aug. 4 On July 27, 2009 Aetna Inc., one ... drop in profit for Q 2 2009. , , ... claim intensity, such as services rendered in a higher cost setting ... for emergency room, ambulatory, laboratory and preventive services." "We are ...
... Expert warns that consequences of osteoporosis go far beyond weak bones, ... a hip have nearly a 25 percent chance of dying in ... five-year death rate for those who have a spinal fracture is ... Aug. 4 issue of the Canadian Medical Association Journal . ...
... , , , , ... of the school year , , ROSEMONT, Ill., Aug. ... to school in the weeks ahead. Shopping for school supplies and ... classes is brewing for both parents and students, mixed with the questions ...
... , ROSEMONT, Ill., Aug. 4 ... such anesthetic drugs as Diprivan (propofol) by the late Michael Jackson, ... agents. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO ... and Maxillofacial Surgeons (AAOMS) and its 8,500 fellows and members who ...
... , , , , ... awareness and research for musculoskeletal diseases , , ... America,s Orthopaedic Services Act of 2009 (AAOS Act), S. 1548, was introduced ... Burr (R-NC). , , This introduction, the first ...
... , , HARRISBURG, Pa., Aug. ... across the state on the new Integrated Care Initiative, an effort ... and Medicaid issues. , , The new health ... create a single source for consumers to work with both agencies, ...
Cached Medicine News:Health News:Aetna 28 Percent Profit Drop Signals Storm Clouds for Healthcare 2Health News:With a Broken Hip Comes Higher Risk for Dying 2Health News:With a Broken Hip Comes Higher Risk for Dying 3Health News:Back-to-School Parents Earn an A+ in Safety: Backpacks, Cheerleading, Football 2Health News:Back-to-School Parents Earn an A+ in Safety: Backpacks, Cheerleading, Football 3Health News:Back-to-School Parents Earn an A+ in Safety: Backpacks, Cheerleading, Football 4Health News:American Association of Oral and Maxillofacial Surgeons Says Only Trained Dental and Medical Practitioners Should Administer and Monitor Anesthesia 2Health News:Access to America's Orthopaedic Services Act of 2009 Introduced in the Senate 2Health News:Access to America's Orthopaedic Services Act of 2009 Introduced in the Senate 3Health News:Pennsylvania Department of Aging Seeks Consumer Input on New Health Care Option 2
... With BareWire technology, the wire crosses ... and delivery catheter. All other actions, including ... stent placement then occur over the wire., ... can break off during a carotid stenting ...
... Designed to fully integrate ... multidisciplinary clinical laboratory working under ... suite uses five core modules ... management and create an environment ...
... chemiluminescence assay for the measurement ... serum. Growth Hormone (GH) is ... the anterior pituitary gland under ... hormone releasing hormone (GHRH) and ...
... DSL's unique DHEA-S-7kits feature ... targeted against the C-7 ... molecule, with no cross-reactivity ... Saliva RIA has been ...
Medicine Products: